BioSpace News Archive

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Jefferies London Healthcare Conference.

Amneal Pharmaceuticals, Inc. announced it has appointed Reem Malki as Senior Vice President, Chief Quality Officer, and Maryll W. Toufanian as Senior Vice President, Regulatory Strategy and Policy.

Personalis, Inc., a leader in advanced genomics for cancer, announced the appointment of Christopher Hall as SVP and Head, Diagnostics Business.

Avivagen Inc. announces that it has closed the second tranche of its previously announced non-brokered private placement financing through the issuance of common shares of the Company at a price of $0.20 per Share (for more information about the Offering and the first tranche thereunder, please see the Company’s news release dated October 21, 2022 for more details.

Monte Rosa Therapeutics, Inc., a biotechnology company developing novel molecular glue degrader-based medicines, announced the company will participate in the following upcoming investor conferences.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the findings of a study that documents the actions clinicians take upon receiving a positive diagnostic genetic testing result for patients with epilepsy.

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the first patient has been dosed with ORM-5029 in a Phase 1 clinical trial for patients with HER2-expressing advanced solid tumors.

Biophytis SA publishes its key financial figures as of 30 June 2022 and announces that the audited consolidated financial statements previously published by the Company for the year ended December 31st, 2021 are being restated to correct the accounting treatment of the Kréos financing agreement signed in November 2021.

BrainChip Holdings Ltd, the world’s first commercial producer of ultra-low power neuromorphic AI IP, announces the appointment of Duy-Loan Le to its Board of Directors, as a non-executive director.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced the pricing of its previously announced underwritten public offering of 6,865,672 shares of Class A common stock at a price to the public of $33.50 per share.